For information visit stridebio.com
Sarepta and StrideBio Announce Multi-target Strategic Collaboration to
Advance Novel Gene Therapies
Sarepta Therapeutics, Inc. and StrideBio, Inc., today announced the signing of a collaboration and license agreement to develop in vivo AAV-based therapies for up to eight central nervous system (CNS) and neuromuscular targets. The parties also plan to focus on strategies intended to address re-dosing challenges in patients who have received AAV-delivered gene therapy. StrideBio will conduct all investigational new drug (IND) enabling research, development and manufacturing for the first four CNS targets, which include NPC1 (Niemann-Pick).